US2010222327A1PendingUtilityA1
Methods of Preparing Pharmaceutical Compositions Comprising Eslicarbazepine Acetate and Methods of Use
Est. expiryMay 6, 2025(expired)· nominal 20-yr term from priority
A61P 25/08A61P 25/18A61P 25/00A61P 25/06A61K 31/19A61K 31/55A61K 45/06
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
Claims
exact text as granted — not AI-modified1 - 29 . (canceled)
30 . A method for the treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.
31 . The method according to claim 30 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours.
32 . A method for the treatment of at least one manic symptom in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.
33 . A method for the maintenance treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.
34 . The method according to claim 33 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours.Join the waitlist — get patent alerts
Track US2010222327A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.